Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
KTX-1161 is a topical ophthalmic solution formulation of SCO-116, a novel Nrf2 activator being developed to treat patients with diseases of the corneal endothelium, including patients with Fuchs’ endothelial corneal dystrophy and patients undergoing cataract surgery.
Lead Product(s): KTX-1161
Therapeutic Area: Ophthalmology Product Name: KTX-1161
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2023